Literature DB >> 15763190

Intraocular retinoblastoma: the case for a new group classification.

A Linn Murphree1.   

Abstract

This article argues the case for the creation of a new group classification of intraocular retinoblastoma. The current Reese-Ellsworth group classification has not been updated since it was published 35 years ago. The proposed classification is based on the natural history of intraocular retinoblastoma and on the risk of loss of the eye following primary therapy.

Entities:  

Mesh:

Year:  2005        PMID: 15763190     DOI: 10.1016/j.ohc.2004.11.003

Source DB:  PubMed          Journal:  Ophthalmol Clin North Am        ISSN: 0896-1549


  142 in total

1.  Association Between Genotype and Phenotype in Consecutive Unrelated Individuals With Retinoblastoma.

Authors:  Flore Salviat; Marion Gauthier-Villars; Matthieu Carton; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Catherine Dehainault; Christine Levy; Lisa Golmard; Isabelle Aerts; François Doz; Fidéline Bonnet-Serrano; Stéphanie Hayek; Alexia Savignoni; Dominique Stoppa-Lyonnet; Claude Houdayer
Journal:  JAMA Ophthalmol       Date:  2020-08-01       Impact factor: 7.389

2.  Comparison of high-risk histopathological features in eyes with primary or secondary enucleation for retinoblastoma.

Authors:  Rachel C Brennan; Ibrahim Qaddoumi; Catherine A Billups; Tammy L Free; Barrett G Haik; Carlos Rodriguez-Galindo; Matthew W Wilson
Journal:  Br J Ophthalmol       Date:  2015-04-14       Impact factor: 4.638

Review 3.  Retinoblastoma, the visible CNS tumor: A review.

Authors:  Helen Dimaras; Timothy W Corson
Journal:  J Neurosci Res       Date:  2018-01-03       Impact factor: 4.164

4.  Tumour size criteria for Group D and E eyes in the International Classification System for Retinoblastoma: effects on rates of globe salvage and high-risk histopathologic features.

Authors:  Jonathan W Kim; Sona N Shah; Sarah Green; John O'Fee; Benita Tamrazi; Jesse L Berry
Journal:  Acta Ophthalmol       Date:  2019-08-17       Impact factor: 3.761

5.  Loss of fundus view as an indication for secondary enucleation in retinoblastoma.

Authors:  Jesse L Berry; Kaitlin Kogachi; Rima Jubran; Jonathan W Kim
Journal:  Pediatr Blood Cancer       Date:  2017-12-08       Impact factor: 3.167

Review 6.  Current treatment and management of retinoblastoma.

Authors:  Dan S Gombos; And Patricia Chevez-Barrios
Journal:  Curr Oncol Rep       Date:  2007-11       Impact factor: 5.075

7.  Distinct Gene Expression Profiles Define Anaplastic Grade in Retinoblastoma.

Authors:  Lauren E Hudson; Pia Mendoza; William H Hudson; Alison Ziesel; G Baker Hubbard; Jill Wells; Bhakti Dwivedi; Jeanne Kowalski; Sandra Seby; Viren Patel; Eldon Geisert; Charles Specht; Hans E Grossniklaus
Journal:  Am J Pathol       Date:  2018-07-21       Impact factor: 4.307

8.  Diagnostic delay and sociodemographic predictors of stage at diagnosis and mortality in unilateral and bilateral retinoblastoma.

Authors:  Marco A Ramírez-Ortiz; M Veronica Ponce-Castañeda; M Lourdes Cabrera-Muñoz; Aurora Medina-Sansón; Xinhua Liu; Manuela A Orjuela
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-02-12       Impact factor: 4.254

Review 9.  Children's Oncology Group's 2013 blueprint for research: rare tumors.

Authors:  Carlos Rodriguez-Galindo; Mark Krailo; Lindsay Frazier; Murali Chintagumpala; James Amatruda; Howard Katzenstein; Marcio Malogolowkin; Logan Spector; Farzana Pashankar; Rebecka Meyers; Gail Tomlinson
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

10.  Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma.

Authors:  Ting-Yi Liang; Xiu-Yu Zhu; Xu-Ming Hua; Xun-Da Ji; Pei-Quan Zhao
Journal:  Int J Ophthalmol       Date:  2020-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.